Researchers from Fox Chase Cancer Center and Temple University have developed a cellular programming approach that creates alloreactive T cells that are able to eliminate leukemic cells without causing graft versus host disease (GvHD).
Using mouse models, the researchers developed a novel approach to improve the desired outcome of allogenic hematopoietic stem cell transplantation and anti-leukemia therapy. Using the cell culture of the donor key immune cell, they were able to develop an approach to reduce the toxicities in alloreactive T cells causing GvHD while still preserving the anti-leukemia activity of the immune cell.
The paper detailing their work was published in the journal Blood, a publication of the American Society of Hematology, on May 3.
“This approach will be useful in the future when developing novel methods for immunotherapy,” said senior study author Yi Zhang, MD, a member of the Fox Chase Epigenetic Program and a senior scientist at Fel’s Institute for Cancer Research and Molecular Biology at Temple University. “This system will not only be useful for reducing GvHD but can also be used in the identification of T cells for the improvement of other types of immunotherapy for advanced cancer.”
PND Wire Services